APR 0 1 2003 THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: JACKOWSKI et al.

INVENTION:

: FIBRINOGEN BIOPOLYMER MARKER PREDICTIVE

RECEIVED

APR 0 3 2003

TECH CENTER 1600/2900

OF TYPE II DIABETES

SERIAL NUMBER

: 09/991,796

FILING DATE

: November 23, 2001

EXAMINER:

: Chernyshev, Olga

GROUP ART UNIT

: 1646

ATTORNEY DOCKET NO.

: 2132.109

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for

in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on 3-37-03

Commissioner for Patents Washington, D.C. 20231

Sir:

Please find enclosed for filing:

X Supplemental Information Disclosure Statement

X Certification Pursuant to 37 C.F.R. §1.97(e)

X Copy of International Search Report

 X
 Certification

 X
 Copy of Interest

 X
 PTO-1449

X References

Respectfully Submitted,

Date: _3/27/2003

Ferris H. Lander

Reg. No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575

PECEIVED APR 03 2003

TOWNSKI et al.

IN RE APPLICANT

INVENTION:

: FIBRINOGEN BIOPOLYMER MARKER PREDIC

OF TYPE II DIABETES

SERIAL NUMBER

: 09/991,796

FILING DATE

: November 23, 2001

EXAMINER:

: Chernyshev, Olga

GROUP ART UNIT

: 1646

ATTORNEY DOCKET NO.

: 2132.109

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a) I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on

Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

3/27/2003

Respectfully Submitted,

Ferris H. Lander Reg. No. 43,377 McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575

HE UNITED STATES PATENT AND TRADEMARK OFFICE APR 03 2003

***CKOWSKI et al.

IN RE APPLICANT

INVENTION:

OF TYPE II DIABETES

SERIAL NUMBER

: 09/991,796

FILING DATE

: November 23, 2001

EXAMINER:

: Chernyshev, Olga

GROUP ART UNIT

: 1646

ATTORNEY DOCKET NO.

: 2132.109

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a) I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner, Patents, Washington, D.C. 20231 on

Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

3/27/2003

Respectfully Submitted,

Ferris H. Lander Reg. No. 43,377 McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402

Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575